These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 1665123)
41. Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria. Qadri SM; Ueno Y; Postle G; Tullo D; San Pedro J Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):372-7. PubMed ID: 8394816 [TBL] [Abstract][Full Text] [Related]
42. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Pankuch GA; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1994 Sep; 38(9):2065-72. PubMed ID: 7811020 [TBL] [Abstract][Full Text] [Related]
43. Comparative in vitro activity of CI934, a new fluoroquinolone, alone and in combination with coumermycin, against gram-positive bacteria. van der Auwera P; Vandermies A; Grenier P; Klastersky J Drugs Exp Clin Res; 1987; 13(3):125-32. PubMed ID: 3622241 [TBL] [Abstract][Full Text] [Related]
44. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. Park HS; Yoon YM; Jung SJ; Kim CM; Kim JM; Kwak JH J Antimicrob Chemother; 2007 Sep; 60(3):568-74. PubMed ID: 17606482 [TBL] [Abstract][Full Text] [Related]
45. Levofloxacin and sparfloxacin: new quinolone antibiotics. Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064 [TBL] [Abstract][Full Text] [Related]
46. Nemonoxacin has potent activity against gram-positive, but not gram-negative clinical isolates. Li ZX; Liu YN; Wang R; Li AM Clin Ter; 2015; 166(6):e374-80. PubMed ID: 26794819 [TBL] [Abstract][Full Text] [Related]
47. [Antibacterial activity of tosufloxacin against fresh clinical isolates]. Yamashiro Y; Shimakura M; Minami S; Fukuoka Y; Yasuda T; Watanabe Y; Narita H; Akama M Jpn J Antibiot; 1994 Mar; 47(3):245-54. PubMed ID: 8182895 [TBL] [Abstract][Full Text] [Related]
48. In vitro activities of PD 117,596 and reference antibiotics against 448 clinical bacterial strains. Smith RP; Baltch AL; Hammer MC; Conroy JV Antimicrob Agents Chemother; 1988 Sep; 32(9):1450-5. PubMed ID: 3196008 [TBL] [Abstract][Full Text] [Related]
49. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. Jones RN; Fritsche TR; Sader HS; Goldstein BP J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188 [TBL] [Abstract][Full Text] [Related]
50. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990. Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351 [TBL] [Abstract][Full Text] [Related]
51. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria]. Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380 [TBL] [Abstract][Full Text] [Related]
52. Comparative antimicrobial activity of gatifloxacin with ciprofloxacin and beta-lactams against gram-positive bacteria. Bassetti M; Dembry LM; Farrel PA; Callan DA; Andriole VT Diagn Microbiol Infect Dis; 2001 Nov; 41(3):143-8. PubMed ID: 11750168 [TBL] [Abstract][Full Text] [Related]
53. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates. Ismaeel NA; Tayeb OS Microbios; 1993; 74(300):147-54. PubMed ID: 8396196 [TBL] [Abstract][Full Text] [Related]
54. [Bactericidal activity of ciprofloxacin and sparfloxacin. Comparison with others active antibiotics against Pasteurella multocida]. Gastine C; Donnio PY; Travert MF; Avril JL Presse Med; 1995 Mar; 24(11):519-22. PubMed ID: 7770389 [TBL] [Abstract][Full Text] [Related]
55. In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients. Rolston KV; Nguyen H; Messer M; LeBlanc B; Ho DH; Bodey GP Antimicrob Agents Chemother; 1990 Nov; 34(11):2263-6. PubMed ID: 2127348 [TBL] [Abstract][Full Text] [Related]
56. Comparative activities of clinafloxacin against gram-positive and -negative bacteria. Ednie LM; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1998 May; 42(5):1269-73. PubMed ID: 9593165 [TBL] [Abstract][Full Text] [Related]
57. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone. Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824 [TBL] [Abstract][Full Text] [Related]
58. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Cagni A; Chuard C; Vaudaux PE; Schrenzel J; Lew DP Antimicrob Agents Chemother; 1995 Aug; 39(8):1655-60. PubMed ID: 7486895 [TBL] [Abstract][Full Text] [Related]
59. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections. Endtz HP; Mouton JW; den Hollander JG; van den Braak N; Verbrugh HA Antimicrob Agents Chemother; 1997 May; 41(5):1146-9. PubMed ID: 9145886 [TBL] [Abstract][Full Text] [Related]
60. In vitro antibacterial activity of DX-619, a novel Des-F (6)-quinolone against clinical isolates in China. Xiao Y; Li Y; Liu J; Zhong W; Yang W J Chemother; 2007 Dec; 19(6):632-42. PubMed ID: 18230543 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]